EcoDrugPlus

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSPREG00000000878
Gene Symbol: HTR7
3 Cross references
196 Possible Orthologues:

60s Ribosomal Protein L12

Ensembl ID : ENSPREG00000009233
Gene Symbol: LOC103460099
3 Cross references
478 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSPREG00000022060
Gene Symbol: LOC103481251
3 Cross references
333 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSPREG00000008655
Gene Symbol: LOC103469352
3 Cross references
334 Possible Orthologues:

60s Ribosomal Protein L22-Like

Ensembl ID : ENSPREG00000013638
Gene Symbol: LOC103461002
2 Cross references
198 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSPREG00000019574
Gene Symbol: LOC103470872
3 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L3

Ensembl ID : ENSPREG00000011570
Gene Symbol: LOC103468999
3 Cross references
335 Possible Orthologues:

60s Ribosomal Protein L5

Ensembl ID : ENSPREG00000013983
Gene Symbol: LOC103464060
3 Cross references
455 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSPREG00000014327
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSPREG00000014847
Gene Symbol: ADAM17
1 Cross references
209 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSPREG00000009792
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSPREG00000001534
Gene Symbol: ADRM1
4 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).